Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Patients With Chronic Cholecystitis and Biliary Tract Dyskinesia

NCT07595003 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT07595003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07595003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Patients With Chronic Cholecystitis and Biliary Tract Dyskinesia
Lead sponsor
Valenta Pharm JSC
Phase
Phase 3
Overall status
Recruiting
Start date
December 12, 2025
Completion date
December 31, 2027
Enrollment
300 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

biliary dyskinesia, chronic cholecystitis